Dosage adjustment during long-term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 141-151

  Sandborn, William J ^a   Colombel, Jean Frédéric ^b   Schreiber, Stefan ^c   Plevy, Scott E ^d   Pollack, Paul F ^e   Robinson, Anne M ^e   Chao, Jingdong ^e   Mulani, Parvez ^e  

^a MAYO CLINIC   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

adalimumab; Crohn's disease; dosage adjustment

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PLACEBO; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEMYELINATION; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; INFLUENZA; INJECTION SITE PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEOPLASM; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 78650159235     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21328     Document Type: Article

References (28)

1. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369: 1627-1640.
2. Baumgart DC, Sandborn WJ,. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369: 1641-1657.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
4. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology. 2006; 130: 323-333.
6. Sandborn WJ, Hanauer SB, Enns R, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial [abstract]. Gut. 2007; 56: 1232-1239.
7. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. PRECISE, 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250. (Pubitemid 47080388)
8. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
9. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238.
10. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829-838.
11. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402-413. (Pubitemid 38182297)
12. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009; 104: 1170-1179.
13. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 1493-1499.
14. Colombel J-F, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009; 58: 940-948.
15. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444.
16. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106: 287-296.
17. Wu EQ, Yu AP, Tang J, et al. Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn's disease. Manag Care Interface. 2008; 21: 20-23.
18. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004; 99: 1984-1989.
19. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239.
20. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007; 26: 1509-1520.
21. Loftus EV Jr, Pan P, Zurawski P, et al. Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn's disease in the United States. J Crohns Colitis. 2009; 3: S7.
22. HUMIRA [summary of product characteristics]. Kent, UK: Abbott Laboratories. Available at: Accessed February 15, 2010.
23. HUMIRA [prescribing information]. North Chicago, IL: Abbott Laboratories; 2010.
24. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1093-1099.
25. Wu EQ, Mulani PM, Yu A, et al. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health. 2008; 11: 820-829.
26. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECiSE 4 results. Gastroenterology. 2007; 132 (4 Suppl 1): A505.
27. Sandborn WJ, D'Haens G, Vermeire S, et al. Regain of response and remission by dose adjustment in patients with Crohn's disease who responded to certolizumab pegol: results from the WELCOME study. Am J Gastroenterol. 2009; 104 (Suppl 3): S450-S451.
28. Sandborn WJ, Vermeire S, D'Haens G, et al. WELCOME: a randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab. Gastroenterology. 2009; 136 (5 Suppl 1): A-27.